No requirement of cyclic conformation of antagonists in binding to vasopressin receptors
- 1 October 1987
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 329 (6142) , 839-840
- https://doi.org/10.1038/329839a0
Abstract
Early reports that acyclic analogues of oxytocin and vasopressin (AVP) have drastically reduced agonistic activities established as dogma that an intact hexapeptide ring structure is essential for the pharmacological activities of analogues of neurohypophysial hormones. Thus, virtually all the many hundreds of agonistic and antagonistic analogues of the neurohypophysial peptides that have been reported contain an intact ring. Here we report that an intact ring is not essential for binding of antagonistic AVP analogues to vasopressor (V1) or antidiuretic (V2) AVP receptors. In fact, one acyclic AVP analogue seems to be about as potent as any previously reported cyclic V2 antagonist. This finding suggests new possibilities for the design of AVP analogues as pharmacological probes and for therapeutic use. Similar modifications might be useful in the design of analogues of other cyclic peptides, such as calcitonin, somatostatin and the atrial natriuretic factors.Keywords
This publication has 13 references indexed in Scilit:
- Selective Agonists and Antagonists of VasopressinPublished by Springer Nature ,1987
- Potent antagonists of vasopressin antidiuretic activity that lack the .beta.,.beta.-cyclopentamethylene-.beta.-mercaptopropionic acid substitution at position 1Journal of Medicinal Chemistry, 1986
- Potent vasopressin antagonists lacking the proline residue at position 7Journal of Medicinal Chemistry, 1986
- Solid Phase SynthesisScience, 1986
- Central target for the behavioural effects of vasopressin neuropeptidesNature, 1984
- Design of more potent antagonists of the antidiuretic responses to arginine-vasopressinJournal of Medicinal Chemistry, 1982
- Vasopressin Analogs That Antagonize Antidiuretic Responses by Rats to the Antidiuretic HormoneScience, 1981
- [1-.beta.-Mercapto-.beta.,.beta.-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocinJournal of Medicinal Chemistry, 1974
- Solid Phase Peptide Synthesis. I. The Synthesis of a TetrapeptideJournal of the American Chemical Society, 1963
- DIFFERENCES IN THE ANTIDIURETIC RESPONSES OF RATS TO THE INTRAVENOUS ADMINISTRATIONOF LYSINE AND ARGININE VASOPRESSINS1Endocrinology, 1958